Abstract 89P
Background
Hepatic arterial infusion chemotherapy (HAIC), transarterial embolization (TAE), and lenvatinib are main treatments in unresectable hepatocellular carcinoma (HCC). This study aims to evaluate the safety and efficacy of HAIC sequential TAE combined with lenvatinib and tislelizumab (an anti-PD-1) as a first-line treatment in patients with high-risk unresectable HCC.
Methods
This is a single-arm, open-label, phase 2 trial (NCT05532319), which is ongoing. Eligible patients with high-risk unresectable HCC (CNLC stage Ib, II and III), ECOG performance status of 0 or 1 and adequate liver function received at least one cycle of HAIC sequential TAE (every 4 weeks) combined with lenvatinib and tislelizumab (200 mg intravenously every 3 weeks). The primary endpoint was the progression-free survival (PFS) rate at six months. Secondary endpoints included objective response rate (ORR), the proportion of patients who underwent curative treatments, significant tumour necrosis, PFS, OS and safety.
Results
Between Nov 1, 2022 and Aug 12, 2023, 35 patients with high-risk unresectable HCC were enrolled. The tumour load of 14 (40%) patients exceeds 50% of the liver volume. The PFS rate at six months was 83.6%. The ORR after one cycle of HAIC sequential TAE was 31.9% (15/47, RECIST 1.1) and 63.8% (30/47, mRECIST). The ORR after two cycle of HAIC sequential TAE was 35.1% (26/40, RECIST 1.1) and 80.0% (32/40, mRECIST). 19 patients (54.3%) received curative treatment after reaching partial response, including 10 (28.6%) curative hepatic resection, 6 (17.1%) radiotherapy, 2 (5.7%) radiofrequency ablation and 1 (2.9%) liver transplantation. Significant tumour necrosis was observed in 100% tumours based on postoperative histopathology in patients who received completed hepatectomy. Median PFS and OS were not reached. Most adverse events were grade 1 or 2. The most common were thrombocytopenia (22.9%), alanine aminotransferase elevating (20%) and serum albumin decreasing (17.1%).
Conclusions
HAIC sequential TAE combined with lenvatinib and tislelizumab is a safe and effective treatment modality in patient with high-risk unresectable HCC.
Legal entity responsible for the study
The authors.
Funding
BGNE.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Presenter: Jitka Palich Fucikova
Session: Poster Display
182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer
Presenter: Louisa Hell
Session: Poster Display
183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_/EMT Modulation
Presenter: Songwei Feng
Session: Poster Display
184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.
Presenter: LUCIA CARRIL AJURIA
Session: Poster Display
185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma
Presenter: Yazan Al Zu’bi
Session: Poster Display
186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUcan sub-project
Presenter: Athénaïs Van Der Elst
Session: Poster Display
187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma
Presenter: Francesca Lucibello
Session: Poster Display
188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment
Presenter: Raya Leibowitz-Amit
Session: Poster Display
189P - The impact of immune microenvironment subopopulations on soft tissue sarcomas
Presenter: Shokhrukhbek Khujaev
Session: Poster Display